Axitinib Experimental Drug Shows Promise In Advanced Kidney Cancer
- From: J <nswex@nalid;anon>
- Date: Wed, 26 Sep 2007 15:56:12 -0400
J wrote:
Positive Axitinib (AG-013736) Results
< http://www.sciencedaily.com/releases/2007/09/070926100542.htm >
Date: September 26, 2007
A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour
fails to respond to the cutting edge therapy.
Ads by Google
Advertise on this site
Recurrent Ovarian Cancer?
See if you qualify for OVATURE, a Phase III clinical trial
www.OVATUREtrial.com
94% of Doctors Don't Know
that you can Beat Stage IV Cancer w/out Chemo, Surgery, or Radiation
www.CancerTruth.net
Breast Cancer Treatment
Comprehensive Info on Breast Cancer Compare Breast Cancer Treatments
BreastCancerTreatments.Biz
Lung Cancer Treatment
Directory of lung cancer treatment options. Get free information.
treatmentlungcancer.com
Breast Cancer Medication
Femara for locally advanced or metastatic breast cancer.
www.femarainfo.com
The study, presented September 26 at the European Cancer Conference in Barcelona, showed that the experimental
drug, axitinib, shrank tumours and delayed progression of the disease in a group of patients who are among the
toughest to treat.
In the study, scientists gave axitinib to 62 patients whose kidney cancer had spread and who had not benefited
from a standard treatment, sorafenib, a targeted therapy designed to disrupt cell division signals in cancer
cells and block the tumour?s ability to form new blood vessels that help it grow. Fourteen of the patients also
had been given ? to no avail ? another similarly targeted drug, sunitinib, after the sorafenib had failed to
work. Axitinib works similarly to the other two but is believed to be more potent.
?More than half the patients ? 51 percent ? experienced tumour shrinkage and in 23 percent of them the
shrinkage is considered significant,? said lead investigator Dr Brian I. Rini, an associate professor of
medicine at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, USA, and a paid member of the
Pfizer scientific advisory board. ?Preliminary analysis shows the progression-free survival was on average more
than 7.7 months. We think these results are impressive because these patients were heavily pre-treated and with
drugs thought to be similar to axitinib.
?The disease progressed in only 24 percent of patients, which we think is low in this kind of setting,? Rini
added. The study found the tumour remained stable in 37 percent of the patients.
?Historically, metastatic kidney cancer has been very tough to treat, with a median survival of 12 months.
Through the results of this trial, it appears that axitinib is a very active drug in renal cell cancer that can
benefit a large number of patients,? Rini added.
The drug?s maker, Pfizer, paid for the study. Axitinib is also being tested in advanced pancreatic, thyroid,
lung and breast cancers.
Note: This story has been adapted from a news release issued by European Cancer Conference.
.
- Prev by Date: Re: Synta says drug (in combination with chemos) delays worsening of melanoma
- Next by Date: This Week's NCI Cancer Bulletin: Sept 25 2007
- Previous by thread: Re: Synta says drug (in combination with chemos) delays worsening of melanoma
- Next by thread: This Week's NCI Cancer Bulletin: Sept 25 2007
- Index(es):
Relevant Pages
|
|
